KLK3 and prostate carcinoma: It has been shown that in 20 patients of recurrent prostate cancer treated with sulforaphane, the time to Prostate-specific antigen (PSA) doubling was longer than that before treatment (6.1 months before treatment vs. 9.6 months during treatment (p = 0.044) (109), indicating that the progression of the disease was slowed down.